Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)

Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists. Objective: establish if there are differences in the impact of COPD on daily activities and morning symptoms measured through questionnaires of daily life activity (Capacity of Daily Living during the Morning (CDLM), Global Chest Symptoms Questionnaire (GCSQ))

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Vitoria-Gasteiz, Alava, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient has signed informed consent form
Patients of both sexes,> 40 years.
Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:

post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) <70%
post-bronchodilator FEV1 <80% (stage II, III and IV)

Exclusion criteria

Participating in an epidemiological study or clinical trial
Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
Patients with mild COPD: FEV1> 80%

Treatment and study plan

Primary outcomes

Determine if there are differences in the impact of COPD on patients according to the characteristics of the disease. To measure the impact of specific self-administered questionnaires used in COPD: CDLMQ, GCSQ and CCQ

Time frame: Retrospective, (previous 24 months)

Capacity of Daily Living during the Morning Qustionnaire (CDLMQ), Global Chest Symptoms Questionnaire (GCSQ)and COPD Control Questionnaire (CCQ)

Secondary outcomes

Assess comorbidities as a risk factor for frequent exacerbations

Time frame: Retrospective, (previous 24 months)

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Impact of Morning Symptoms in Clinical Control of COPD

Acronym: IMPAEPOC

Important dates

Study start: 2010
Study completion: 2011
First posted: Dec 24, 2010
Registry last updated: Aug 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed